Shah, Mithun Vinod http://orcid.org/0000-0002-5359-336X
Tran, Elizabeth Ngoc Hoa http://orcid.org/0000-0003-1644-2287
Shah, Syed
Chhetri, Rakchha
Baranwal, Anmol http://orcid.org/0000-0002-3432-0489
Ladon, Dariusz
Shultz, Carl
Al-Kali, Aref
Brown, Anna L. http://orcid.org/0000-0002-9023-0138
Chen, Dong
Scott, Hamish S. http://orcid.org/0000-0002-5813-631X
Greipp, Patricia http://orcid.org/0000-0002-5536-9011
Thomas, Daniel
Alkhateeb, Hassan B.
Singhal, Deepak
Gangat, Naseema http://orcid.org/0000-0002-9104-6172
Kumar, Sharad http://orcid.org/0000-0001-7126-9814
Patnaik, Mrinal M. http://orcid.org/0000-0001-6998-662X
Hahn, Christopher N. http://orcid.org/0000-0001-5105-2554
Kok, Chung Hoow http://orcid.org/0000-0002-3181-7852
Tefferi, Ayalew http://orcid.org/0000-0003-4605-3821
Hiwase, Devendra K. http://orcid.org/0000-0002-6666-3056
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA15083)
Mayo Clinic | Center for Clinical and Translational Science, Mayo Clinic
CSL Centenary Fellowship Medical Research Futures Fund Leukemia-Lymphoma Translational Research Program
Department of Health | National Health and Medical Research Council (GNT2007739, MRF1195517)
Cancer Australia
Leukaemia Foundation
Article History
Received: 19 January 2023
Revised: 15 March 2023
Accepted: 17 March 2023
First Online: 11 April 2023
Competing interests
: MVS—Research funding to the institution from AbbVie, Celgene, MRKR Therapeutics, and Astellas; AA—Research support to institution (Novartis, Astex); MP—Membership on an entity’s Board of Directors or advisory committees (Stemline Therapeutics) and Research funding (Kura Oncology); DH—Membership on an entity’s Board of Directors or advisory committees (AbbVie, Novartis). All other authors disclose no conflicts of interest.